10-K: Novavax Reports 2024 Results, Highlights Sanofi Partnership and Pipeline Progress

Novavax's 2024 10-K filing details financial results, strategic shifts including a major Sanofi partnership, and ongoing development of its vaccine pipeline.

Summary

• Novavax reported a net loss of $187.5 million for 2024, a significant decrease from the $545.1 million loss in 2023 and $657.9 million in 2022.
• Revenue for 2024 totaled $682.2 million, down from $983.7 million in 2023, primarily due to decreased COVID-19 vaccine sales, offset by revenue from the Sanofi collaboration.
• The company is focusing on a partnership with Sanofi, leveraging its technology platform for additional partnerships, and advancing its early-stage pipeline.
• Novavax has $1.0 billion in committed APAs anticipated for future delivery under existing agreements.
• The company is advancing its COVID-19-Influenza (CIC) vaccine candidate and stand-alone influenza vaccine candidate, initiating a Phase 3 trial in December 2024.
• Novavax is also pursuing early-stage research in diseases such as RSV, varicella-zoster virus, and C. Diff. colitis.
• The company has identified a material weakness in its internal control over financial reporting related to IT general controls.
• Novavax has 952 full-time employees as of February 18, 2025.
• The company is subject to various government regulations, including those related to product safety, efficacy, and manufacturing.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company has made progress in some areas, such as securing a partnership with Sanofi and advancing its pipeline, it also faces significant challenges, including declining revenue, ongoing losses, and regulatory hurdles. The sentiment is neutral to slightly positive.

Positives

• The net loss decreased significantly in 2024 compared to previous years.
• The Sanofi collaboration provides a strong commercial partner and potential revenue streams.
• Advancement of the CIC and stand-alone influenza vaccine candidates into Phase 3 trials.
• Receipt of EUA for the updated COVID-19 vaccine.
• The company has a significant amount of cash and marketable securities on hand.

Negatives

• Revenue decreased in 2024 compared to 2023.
• The company has a history of losses and future profitability is uncertain.
• A material weakness in internal control over financial reporting was identified.
• The company is dependent on third parties for manufacturing and distribution.
• There is significant competition in the vaccine market.

Risks

• The regulatory and commercial success of the COVID-19 vaccine remains uncertain.
• The company may not succeed in obtaining full U.S. FDA licensure or foreign regulatory approvals.
• Product candidates might fail to meet their primary endpoints in clinical trials.
• The company may be adversely affected by natural or man-made disasters or public health emergencies.
• The company's stock price has been and will likely continue to be highly volatile.

Future Outlook

Novavax expects to continue to focus on its partnership with Sanofi, leverage its technology platform for additional partnerships, and advance its early-stage pipeline. The company anticipates future operations to be funded primarily by milestone payments, royalties, product sales, and other potential funding sources.

Industry Context

The vaccine market is intensely competitive, characterized by rapid technological progress. Novavax faces competition from major pharmaceutical companies, specialized biotechnology firms, academic institutions, government agencies and private and public research institutions.

Comparison to Industry Standards

• Novavax is one of three manufacturers that have a COVID-19 vaccine that has received authorization by the U.S. FDA for the 2024-2025 vaccination season, with the other manufacturers being Pfizer and Moderna.
• As of February 2025, the U.S. FDA has granted Pfizer and Moderna BLA approval for their updated vaccines in individuals 12 years and older and EUA for their updated vaccines in individuals 6 months to 11 years, while Novavax received EUA by the U.S. FDA for our updated COVID-19 vaccine in individuals 12 years and older.
• Other manufacturers who are actively developing a COVID-19-influenza combination vaccine candidate in Phase 3 trials and are working with the U.S FDA for regulatory approval and commercialization, include Moderna and Pfizer.

Legal Proceedings

• The parties ultimately negotiated a settlement, which the Maryland Court approved on May 23, 2024. The Maryland Court closed the Sinnathurai Action on May 24, 2024.
• On December 12, 2024, the court entered an order granting preliminary approval of the derivative settlement and setting a date for a hearing on the final approval of the settlement. The hearing for final consideration of the proposed settlement is presently scheduled to be held on March 7, 2025, at 9:30 a.m. EST at the United States District Court for the District of Maryland, Southern Division, 650 Cherrywood Lane, Greenbelt, MD 20770.

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance and strategic decisions.
• Employees may be affected by workforce reductions and changes in the company's operating model.
• Customers and partners will be impacted by the availability and effectiveness of Novavax's vaccines.

Next Steps

• Continue commercializing updated COVID-19 vaccine through the end of the 2024-2025 vaccination season.
• Advance CIC and stand-alone influenza vaccine candidates to BLA filing and commercialization through partnerships.
• Continue preclinical development of H5N1 avian pandemic influenza program.
• Advance early-stage preclinical research for RSV combinations, varicella-zoster virus (shingles) and C. Diff. colitis vaccine candidates.
• Continue technology transfer of manufacturing process for the COVID-19 Vaccine Products to Sanofi.

Key Dates